Compare Viatris Inc (VTRS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Viatris Inc trades at $16.28 (market cap $18.69B), while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: Viatris Inc pays a 2.95% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Viatris Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| VTRS | XHB | |
|---|---|---|
Market Cap | $18.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.86 | $121.36 |
52-Week Low | $9.49 | $94.86 |
Enterprise Value | $30.80B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
XHB trades at $108.71 with a modest 0.43% daily gain, showing bullish technical momentum with strong moving average signals. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overbought conditions with RSI at 71.56, suggesting potential near-term consolidation.
The housing sector outlook remains cautiously optimistic with legislative support and improving builder sentiment offsetting high mortgage rate concerns. Key risks include interest rate sensitivity and inventory constraints, while institutional positioning adjustments reflect strategic portfolio rebalancing rather than sector pessimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
